A Systematic Analysis Workflow for High-Density Customized Protein Microarrays in Biomarker Screening.

Analysis Antibodies Biomarker Fluorescence Normalization Protein microarray Proteome Proteomics

Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 3 10 2018
pubmed: 3 10 2018
medline: 5 6 2019
Statut: ppublish

Résumé

High-density protein microarrays constitute a promising high-throughput platform for the characterization of protein expression patterns, biomarker discovery, and validation. Different types of protein microarrays have been described according to several features (such as content, format, and detection system) presenting advantages and disadvantages which are relevant for the specific application and purposes. Therefore, an experimental design is key for any screening based on protein microarrays assays; in fact, the data analysis strategy is directly related to the experimental design, type of protein microarray and consequently the final outcome, the data and results interpretation, is also directly linked. Here, it is proposed a systematic workflow for biomarker discovery based on tailor-made protein microarrays platforms which obtain comprehensively info for the functional protein characterization in high-throughput format.

Identifiants

pubmed: 30276735
doi: 10.1007/978-1-4939-8814-3_7
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-122

Auteurs

Rodrigo García-Valiente (R)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.

Jonatan Fernández-García (J)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.

Javier Carabias-Sánchez (J)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.

Alicia Landeira-Viñuela (A)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
Department of Medicine and Cytometry General Service-NUCLEUS, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.

Rafael Góngora (R)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
Department of Medicine and Cytometry General Service-NUCLEUS, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.

María Gonzalez-Gonzalez (M)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. mariagg@usal.es.
Department of Medicine and Cytometry General Service-NUCLEUS, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. mariagg@usal.es.

Manuel Fuentes (M)

Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
Department of Medicine and Cytometry General Service-NUCLEUS, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.

Articles similaires

C-Reactive Protein Humans Biomarkers Inflammation
Humans Retrospective Studies Male Critical Illness Female
Humans Male Female Intensive Care Units COVID-19

Classifications MeSH